Physician profile
Akinola E Ojeleye
NPI 1851327118
$2,954.49
in general payments reported to CMS, 2019-2025
40 companies · $178 in 2025
The $178 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $353 · 2021: $623 · 2022: $639 · 2023: $571 · 2024: $212 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $563.07 | 2021-2025 | |
| Novo Nordisk INC | $417.47 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $192.80 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $141.37 | 2019-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $132.54 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $129.86 | 2019-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $124.90 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $109.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $94.94 | 2019-2023 | Vaxneuvance, Gardasil 9, Belsomra |
| Lilly USA, LLC | $91.71 | 2021-2023 | Mounjaro |
| Sanofi-Aventis U.S. LLC | $86.81 | 2019-2022 | |
| Abbott Laboratories | $71.46 | 2022-2023 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.76 | 2020-2024 | Jardiance |
| Glaxosmithkline, LLC. | $53.96 | 2019-2025 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $52.39 | 2020-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akinola Ojeleye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.